Price$4.00+0.01 (+0.38%)
02:15 PM03:45 PM
News · 26 weeks35+200%
2026-03-012026-08-23
Mix1590d
- SEC Filings11(73%)
- Other4(27%)
Latest news
25 items- SECGenprex Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Genprex, Inc. (0001595248) (Filer)
- PRGenprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene TherapyCollaboration Allows Genprex to Accelerate Manufacturing Processes for IND-Enabling Preclinical Studies and Future Clinical TrialsAUSTIN, Texas, Aug. 18, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it has entered into a development and manufacturing agreement with a leading U.S. based clinical and commercial Contract Development and Manufacturing Organization (CDMO) to initiate the manufacturing scale-up of its diabetes gene therapy program. This strategic selection allows for the transition of the Company's therape
- SECSEC Form 10-Q filed by Genprex Inc.10-Q - Genprex, Inc. (0001595248) (Filer)
- SECGenprex Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits8-K - Genprex, Inc. (0001595248) (Filer)
- SECGenprex Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Genprex, Inc. (0001595248) (Filer)
- PRGenprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation StudiesCollaboration Advances Biomarker-Driven Patient Selection and Precision Medicine in OncologyValidation Studies Aim to Optimize Clinical Trial Patient Selection CriteriaAUSTIN, Texas, Aug. 3, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced its collaboration with Roche Diagnostics to validate biomarkers for patient selection in clinical trials for non-small cell lung cancer (NSCLC). Building on promising preclinical and clinical data, this collaboration intends to refine patient identification using TROP2 as a biomarker.
- SECGenprex Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits8-K - Genprex, Inc. (0001595248) (Filer)
- SECGenprex Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Genprex, Inc. (0001595248) (Filer)
- SECSEC Form S-8 filed by Genprex Inc.S-8 - Genprex, Inc. (0001595248) (Filer)
- SECGenprex Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Genprex, Inc. (0001595248) (Filer)
- PRGenprex Receives a Notice of Allowance from The Canadian Intellectual Property Office for a Patent Claiming the Combination of Reqorsa® Gene Therapy with Either PD-1 or PD-L1 Antibodies to Treat CancerPatent Covers Acclaim-3 Clinical Trials Combining REQORSA Gene Therapy with Genentech, Inc.'s Tecentriq®AUSTIN, Texas, June 22, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that The Canadian Intellectual Property Office (CIPO) has issued a Notice of Allowance to Genprex for a patent covering the use of Reqorsa® Gene Therapy (quaratusugene ozeplasmid) in combination with either PD-1 or PD-L1 antibodies for the treatment of both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
- SECGenprex Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Genprex, Inc. (0001595248) (Filer)
- PRGenprex to Participate at BIO International Convention 2026The BIO International Convention Brings Together More Than 20,000 Biotech Industry Leaders From Around The WorldAUSTIN, Texas, June 17, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its team will be attending and participating at the BIO 2026 International Convention taking place June 22-25, 2026 in San Diego, California. In attendance from Genprex's executive leadership team will be Thomas Gallagher, Senior Vice President of Intellectual Property and Li
- SECGenprex Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits8-K - Genprex, Inc. (0001595248) (Filer)
- SECSEC Form S-3 filed by Genprex Inc.S-3 - Genprex, Inc. (0001595248) (Filer)
- SECGenprex Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Genprex, Inc. (0001595248) (Filer)
- PRPositive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 ASCO Annual MeetingTrop-2 H-scores Above 100 and PTEN H-scores Below 100 Correlated With Longer Progression Free Survival in Non-Small Cell Lung Cancer Patients Identified Biomarkers May Predict Patient Response, Enable Targeted Patient Selection and Allow for Precision Medicine AUSTIN, Texas, May 26, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators' abstract was published at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The abstract details positive clinical data from studies of predicti
- SECGenprex Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Genprex, Inc. (0001595248) (Filer)
- PRGenprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual MeetingPdx1/MafA Gene Therapy Reversed Hyperglycemia in Type 2 Diabetic Models Within Four WeeksAUSTIN, Texas, May 14, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators presented positive preclinical data on the Company's diabetes gene therapy drug candidate at the 2026 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting. The collaborators presented preclinical data demonstrating that the diabetes gene therapy (Pdx1/MafA gene therapy, PM or GPX-002) can reverse hyperglycemia in Type 2 dia
- SECSEC Form 10-Q filed by Genprex Inc.10-Q - Genprex, Inc. (0001595248) (Filer)
- SECGenprex Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Genprex, Inc. (0001595248) (Filer)
- PRGenprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat CancerStrengthens Patent Estate and Expands Protection in Another Target MarketAUSTIN, Texas, April 30, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that The Israel Patent Office (ILPO) has granted Genprex a patent covering the use of Reqorsa® Gene Therapy (quaratusugene ozeplasmid) in combination with PD-1 antibodies for the treatment of cancer. "Securing this patent in Israel further solidifies Genprex's robust
- SECSEC Form DEF 14A filed by Genprex Inc.DEF 14A - Genprex, Inc. (0001595248) (Filer)
- SECGenprex Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Genprex, Inc. (0001595248) (Filer)
- PRGenprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual MeetingPdx1/MafA Gene Therapy Reversed Hyperglycemia in Type 2 Diabetic Models Within Four WeeksAUSTIN, Texas, April 28, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators will present positive preclinical data on the Company's diabetes gene therapy drug candidate at the upcoming 2026 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, taking place May 11-15, 2026 in Boston, Mass. The collaborators will present preclinical data demonstrating that the diabetes gene therapy (Pdx1/MafA gene t
GNPX FAQ
6 questionsWhat does Genprex Inc. do?
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes who currently have limited treatment options. The company works with institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Its lead product candidate is REQORSA (GPX-001), which is in preclinical stage for the treatment of non-small cell...Where does GNPX stock trade?
Genprex Inc. (GNPX) is listed on NASDAQ.What sector and industry is GNPX in?
Genprex Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Genprex Inc. go public?
Genprex Inc. (GNPX) completed its IPO in 2018.What companies are similar to GNPX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare GNPX side-by-side with any of them on Quantisnow.How can I track GNPX on Quantisnow?
Quantisnow aggregates Genprex Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GNPX to receive live email and push alerts on every new disclosure.